Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2018-10-08 12:31:052018-10-08 16:50:49GSK Funds New Startup with Immunometabolic Focus